Jiang, Liang team published research in Acta Pharmaceutica Sinica B in 2021 | 4224-70-8

Computed Properties of 4224-70-8, 6-bromohexanoic acid is an organobromine compound comprising hexanoic acid having a bromo substituent at the 6-position. It derives from a hexanoic acid.
6-Bromohexanoic acid is a useful research compound. Its molecular formula is C6H11BrO2 and its molecular weight is 195.05 g/mol. The purity is usually 95%.
6-Bromohexanoic acid is useful for the preparation of anti-CTLA4 compounds as antitumor agents.
6-Bromohexanoic acid is a fatty acid that has been shown to be an effective agent for the treatment of cancer. It is used in gene therapy to inhibit the growth of cancer cells by binding to and then activating transcription factors. 6-Bromohexanoic acid can also be used as a chemotherapeutic agent and has been shown to cause apoptosis in monoclonal antibody-treated cells. 6-Bromohexanoic acid has pharmacokinetic properties that are similar to those of other fatty acids. The reaction solution was found to have high chemical stability, which may be due to the presence of nitrogen atoms. This reaction solution was found to adsorb onto the surface of monoclonal antibodies and cell culture, altering their properties., 4224-70-8.

Organobromine compounds, also called organobromides, are organic compounds that contain carbon bonded to bromine. 4224-70-8, formula is C6H11BrO2, The most pervasive is the naturally produced bromomethane. Computed Properties of 4224-70-8

Jiang, Liang;Wang, Yuting;Li, Qian;Tu, Zhengchao;Zhu, Sihua;Tu, Sanfang;Zhang, Zhang;Ding, Ke;Lu, Xiaoyun research published ã€?Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutationã€? the research content is summarized as follows. Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clin. challenge for the treatment of chronic myeloid leukemia (CML). Chem. degradation of Bcr-AblT315I protein has become a potential strategy to overcome drug resistance. Herein, we first described the design, synthesis, and evaluation of a new class of selective Bcr-AblT315I proteolysis-targeting chimeric (PROTAC) degraders based on GZD824 (reported as Bcr-AblT315I inhibitor by our group). One of the degrader 7o with 6-member carbon chain linkage with pomalidomide exhibits the most potent degradation efficacy with DR of 69.89% and 94.23% at 100 and 300 nmol/L, resp., and has an IC50 value of 26.8 ± 9.7 nmol/L against Ba/F3T315I cells. Further, 7o also displays substantial tumor regression against Ba/F3-Bcr-AblT315I xenograft model in vivo.

Computed Properties of 4224-70-8, 6-bromohexanoic acid is an organobromine compound comprising hexanoic acid having a bromo substituent at the 6-position. It derives from a hexanoic acid.
6-Bromohexanoic acid is a useful research compound. Its molecular formula is C6H11BrO2 and its molecular weight is 195.05 g/mol. The purity is usually 95%.
6-Bromohexanoic acid is useful for the preparation of anti-CTLA4 compounds as antitumor agents.
6-Bromohexanoic acid is a fatty acid that has been shown to be an effective agent for the treatment of cancer. It is used in gene therapy to inhibit the growth of cancer cells by binding to and then activating transcription factors. 6-Bromohexanoic acid can also be used as a chemotherapeutic agent and has been shown to cause apoptosis in monoclonal antibody-treated cells. 6-Bromohexanoic acid has pharmacokinetic properties that are similar to those of other fatty acids. The reaction solution was found to have high chemical stability, which may be due to the presence of nitrogen atoms. This reaction solution was found to adsorb onto the surface of monoclonal antibodies and cell culture, altering their properties., 4224-70-8.

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary